Champions Oncology (NASDAQ:CSBR) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.
Risk and Volatility
Champions Oncology has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 2.7, suggesting that its share price is 170% more volatile than the S&P 500.
This table compares Champions Oncology and ADMA Biologics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for Champions Oncology and ADMA Biologics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Champions Oncology currently has a consensus price target of $13.13, suggesting a potential upside of 149.52%. ADMA Biologics has a consensus price target of $10.20, suggesting a potential upside of 136.66%. Given Champions Oncology’s higher probable upside, analysts clearly believe Champions Oncology is more favorable than ADMA Biologics.
Earnings and Valuation
This table compares Champions Oncology and ADMA Biologics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Champions Oncology||$27.07 million||2.26||$130,000.00||$0.01||526.00|
|ADMA Biologics||$16.99 million||15.05||-$65.74 million||($1.45)||-2.97|
Champions Oncology has higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Champions Oncology, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
51.6% of Champions Oncology shares are held by institutional investors. Comparatively, 59.1% of ADMA Biologics shares are held by institutional investors. 44.3% of Champions Oncology shares are held by company insiders. Comparatively, 15.2% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Champions Oncology beats ADMA Biologics on 9 of the 14 factors compared between the two stocks.
About Champions Oncology
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The company also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying potentially useful drugs. In addition, it offers Translational Oncology Solutions, including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies. Champions Oncology, Inc. markets its products through Internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
About ADMA Biologics
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also offers Nabi-HB, a hyperimmune globulin for the treatment of acute exposure; and Bivigam, an intravenous immune globulin for the treatment of primary humoral immunodeficiency. In addition, it operates source plasma collection facilities in Norcross, Marietta, and Kennesaw, Georgia. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.